enGene (ENGN) announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025. Dr. Sweiti most recently served as Global Medical Head, Oncology Clinical Development at Johnson & Johnson (JNJ).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- enGene price target lowered to $18 from $19 at Morgan Stanley
- Buy Rating for enGene Holdings: Strategic Positioning and Competitive Edge in NMIBC Market
- enGene Holdings Reports Q3 2025 Results and Milestones
- enGene Holdings Achieves Key Milestone in LEGEND Trial and Secures RMAT Designation